Opko Health shares rise 2.61% intraday after announcing abstract selection for ESPEN Congress.

Opko Health, Inc. rose 2.61% intraday, with the company announcing that their abstract 'First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome' has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism ('ESPEN') Congress. The oral GLP-2 tablet program combines a proprietary long-acting GLP-2 agonist developed by OPKO with Entera's proprietary N-Tab technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption.